We are live on ! Find out more
CTMX icon

CytomX Therapeutics
CTMX

119 hedge funds and large institutions have $299M invested in CytomX Therapeutics in 2019 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 44 increasing their positions, 35 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

35% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 17

26% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 35

13% more capital invested

Capital invested by funds: $264M → $299M (+$34.7M)

5% more funds holding

Funds holding: 113 → 119 (+6)

0.33% more ownership

Funds ownership: 78.92% → 79.25% (+0.33%)

Holders
119
Holders Change
+6
Holders Change %
+5.31%
% of All Funds
2.34%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
23
Increased
44
Reduced
35
Closed
17
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
First Manhattan
First Manhattan
New York
+$6.6M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
+$4.86M
3
Renaissance Technologies
Renaissance Technologies
New York
+$3.58M
4
PAM
Panagora Asset Management
Massachusetts
+$3.26M
5
EC
EcoR1 Capital
California
+$2.77M

Top Sellers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
-$27.5M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$10.2M
3
BI
BVF Inc
California
-$7.5M
4
State Street
State Street
Massachusetts
-$3.72M
5
SIM
Spark Investment Management
New York
-$901K
Name Holding Trade Value Shares
Change 		Change in
Stake
Marshall Wace
26
Marshall Wace
United Kingdom
$3.34M +$2.65M +393,401 +4,902%
Goldman Sachs
27
Goldman Sachs
New York
$3.33M +$79.1K +11,725 +3%
JP Morgan Chase
28
JP Morgan Chase
New York
$3.07M +$1.58M +234,743 +175%
Millennium Management
29
Millennium Management
New York
$2.69M +$1.76M +260,709 +412%
Man Group
30
Man Group
United Kingdom
$2.67M +$2.09M +310,309 +2,999%
Two Sigma Investments
31
Two Sigma Investments
New York
$2.58M +$1.58M +234,381 +307%
Charles Schwab
32
Charles Schwab
California
$2.12M -$115K -17,103 -6%
Assenagon Asset Management
33
Assenagon Asset Management
Luxembourg
$1.87M +$1M +148,740 +196%
Jacobs Levy Equity Management
34
Jacobs Levy Equity Management
New Jersey
$1.84M +$927K +137,408 +164%
OAM
35
Oxford Asset Management
United Kingdom
$1.76M +$903K +133,900 +171%
Acadian Asset Management
36
Acadian Asset Management
Massachusetts
$1.69M +$742K +109,909 +117%
SIM
37
Spark Investment Management
New York
$1.69M -$901K -133,564 -40%
BBA
38
Baker Bros. Advisors
New York
$1.61M – – –
Bank of New York Mellon
39
Bank of New York Mellon
New York
$1.57M -$29.7K -4,408 -2%
Deutsche Bank
40
Deutsche Bank
Germany
$1.48M -$136K -20,099 -10%
Massachusetts Financial Services
41
Massachusetts Financial Services
Massachusetts
$1.46M -$128K -19,006 -10%
GIM
42
Granahan Investment Management
Massachusetts
$1.28M +$2.84K +421 +0.3%
Squarepoint
43
Squarepoint
New York
$1.23M -$354K -52,451 -26%
PAG
44
Private Advisor Group
New Jersey
$1.18M -$627 -93 -0.1%
AQR Capital Management
45
AQR Capital Management
Connecticut
$1.09M +$519K +76,900 +141%
Wellington Management Group
46
Wellington Management Group
Massachusetts
$1.08M -$27.5M -4,069,019 -97%
CS
47
Credit Suisse
Switzerland
$1.04M +$244K +36,191 +40%
GCP
48
GSA Capital Partners
United Kingdom
$968K +$260K +38,519 +49%
DCM
49
DAFNA Capital Management
California
$831K – – –
MCM
50
Moore Capital Management
New York
$831K – – –
1
2
3 4 5

CTMX Hedge Fund Activity: Q4 2019 in Review

119 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q4 2019, worth a combined $299M — up 13% from $264M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new CTMX positions and 17 closed out — a net gain of 6 holders — while 44 added to existing stakes and 35 trimmed.

The largest buyer was First Manhattan, opening a new position worth an estimated $6.6M. The largest seller was Wellington Management Group, cutting an estimated $27.5M.

  • 119 institutional investors held CytomX Therapeutics (CTMX) as of Q4 2019, up from 113 in Q3 2019.
  • Funds reported $299M of CytomX Therapeutics stock for Q4 2019, up 13% quarter-over-quarter.
  • 23 funds opened new CytomX Therapeutics positions in Q4 2019 and 17 closed out, a net change of +6 holders.
  • The largest CytomX Therapeutics buyer in Q4 2019 was First Manhattan, an estimated $6.6M added.
  • The largest CytomX Therapeutics seller in Q4 2019 was Wellington Management Group, an estimated $27.5M sold.

Based on aggregated 13F filings for Q4 2019.